Switzerland (CH)

Explaining the extended GeV gamma-ray emission adjacent to HESS J1825-137 (2021) Collins T, Rowell G, Mitchell AMW, Voisin F, Fukui Y, Sano H, Alsulami R, Einecke S Journal article, Original article A FRAMEWORK OF POTENTIAL INTERVENTIONS TO ACCELERATE GENDER-EQUITABLE CAREER ADVANCEMENT IN ACADEMIC RHEUMATOLOGY (2021) Ovseiko PV, Gossec L, Andreoli L, Kiltz U, Van Mens L, Hassan N, Van Der Leeden M, et al. Conference contribution LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY (2021) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen P, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL (2021) Boers M, Conaghan PG, Schett G, Mandl P, Naredo E, Van Den Bosch F, Burgos-Vargas R, et al. Conference contribution TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY (2021) D'Agostino MA, Conaghan PG, Gaillez C, Boers M, Naredo E, Carron P, Hanova P, et al. Conference contribution ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED (2021) Kaeley GS, Schett G, Conaghan PG, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution ENGRAILED 1 COORDINATES CYTOSKELETAL ORGANIZATION TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND FIBROTIC TISSUE REMODELING (2021) Györfi AH, Matei AE, Fuchs M, Rigau A, Hong X, Honglin Z, Luber M, et al. Conference contribution EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ROTATOR CUFF TENDINOPATHY: A 24-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II PROOF-OF-CONCEPT TRIAL (2021) Millar NL, Mcinnes I, Mindeholm L, Seroutou A, Praestgaard J, Schramm U, Levitch R, et al. Conference contribution 68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Conference contribution EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT (2021) Kuster S, Jordan S, Elhai MD, Held U, Steigmiller K, Bruni C, Iannone F, et al. Conference contribution